Oxular was acquired by Regeneron in January 2025. To continue following for updated information, please visit Regeneron’s LinkedIn. www.linkedin.com/company/regeneron-pharmaceuticals/
“One treatment a year. Life changing.”
Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery.
This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.
Company Details
- Employees
- 4
- Address
- Magdalen Centre, 1 Robert Robinson Avenue, Oxford,england Ox4 4ga,united Kingdom
- Industry
- Biotechnology
- Website
- http://www.oxular.com
- Keywords
- Ophthalmology, Biotechnology, Ocular, DME, Diabetic macular edema, Retinoblastoma, Microreservoirs, OxuLumis, OxuFlo, AMD, Age-related Macular Degeneration, Retinal disease, Therapeutics, Treatment, Anti-VEGF, Gene therapy, Uveitis, Uveal melanoma, Retinal inflammation.
- HQ
- Oxford, England
Oxular Questions
Oxular's website is http://www.oxular.com
Oxular's LinkedIn profile is https://uk.linkedin.com/company/oxular
Oxular has
4 employees.
View email and phone details for 4
employees at Oxular.
Oxular's industry is
Biotechnology
Oxular's top competitors are
Jemincare,
Imagene Biopharmaceuticals,
Capricor Therapeutics, Inc.,
Hikma Pharmaceuticals,
Verastem Oncology,
Immedica Pharma Ab,
Innovent Biologics,
Rapt Therapeutics,
Ikena Oncology,
Regeneron.
Oxular's categories are Biotechnology
